These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24846335)

  • 21. Antibodies to watch in 2024.
    Crescioli S; Kaplon H; Chenoweth A; Wang L; Visweswaraiah J; Reichert JM
    MAbs; 2024; 16(1):2297450. PubMed ID: 38178784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commercial development considerations for biotechnology-derived therapeutics.
    Marafino BJ; Pugsley MK
    Cardiovasc Toxicol; 2003; 3(1):5-12. PubMed ID: 12668886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metrics for antibody therapeutics development.
    Reichert JM
    MAbs; 2010; 2(6):695-700. PubMed ID: 20930555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India.
    Kalaivani M; Singh A; Kalaiselvan V
    MAbs; 2015; 7(1):276-80. PubMed ID: 25523367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.
    Scott BJ; Klein AV; Wang J
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S123-32. PubMed ID: 24965228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic monoclonal antibodies: trends in development and approval in the US.
    Reichert JM
    Curr Opin Mol Ther; 2002 Apr; 4(2):110-8. PubMed ID: 12044031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The therapeutic monoclonal antibody market.
    Ecker DM; Jones SD; Levine HL
    MAbs; 2015; 7(1):9-14. PubMed ID: 25529996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Siltuximab: first global approval.
    Markham A; Patel T
    Drugs; 2014 Jul; 74(10):1147-52. PubMed ID: 24958337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development trends for human monoclonal antibody therapeutics.
    Nelson AL; Dhimolea E; Reichert JM
    Nat Rev Drug Discov; 2010 Oct; 9(10):767-74. PubMed ID: 20811384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibodies to watch in 2010.
    Reichert JM
    MAbs; 2010; 2(1):84-100. PubMed ID: 20065640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Regulatory consequences for the use of monoclonal antibodies].
    Lackner F; Behr-Gross ME
    Med Sci (Paris); 2009 Dec; 25(12):1183-8. PubMed ID: 20035703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
    Deisseroth A; Ko CW; Nie L; Zirkelbach JF; Zhao L; Bullock J; Mehrotra N; Del Valle P; Saber H; Sheth C; Gehrke B; Justice R; Farrell A; Pazdur R
    Clin Cancer Res; 2015 Mar; 21(5):950-4. PubMed ID: 25601959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Development and Regulatory Pathways of Monoclonal Antibodies in Japan.
    Liao H; Li Z
    Ther Innov Regul Sci; 2022 Mar; 56(2):173-183. PubMed ID: 34825323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibodies as innovative therapeutics.
    Reichert JM
    Curr Pharm Biotechnol; 2008 Dec; 9(6):423-30. PubMed ID: 19075682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
    Queirolo P; Tanda ET
    Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Licensed monoclonal antibodies and associated challenges.
    Khan AH; Sadroddiny E
    Hum Antibodies; 2015 Dec; 23(3-4):63-72. PubMed ID: 27472864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
    Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
    BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Market watch: Upcoming market catalysts in Q4 2015.
    Liu M
    Nat Rev Drug Discov; 2015 Oct; 14(10):671. PubMed ID: 26338153
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.